Tempus AI, Inc. (TEM)
| Market Cap | 5.78B |
| Revenue (ttm) | 562.02M |
| Net Income (ttm) | -293.25M |
| Shares Out | 165.10M |
| EPS (ttm) | -1.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,189,922 |
| Open | 32.51 |
| Previous Close | 30.83 |
| Day's Range | 31.25 - 35.17 |
| 52-Week Range | 22.89 - 43.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 17, 2024 |
About TEM
Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we cons... [Read more]
News
SoftBank Group launches AI healthcare joint venture with Tempus AI
Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to analyse personal medical data with artificial intelligence (AI) to come up with treatment recommend...
Revere Payments Named BigCommerce Preferred Technology Partner
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Revere Payments helps fast-growing BigCommerce customers streamline payment processes and improve transaction security and enhance customer experience.
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Admini...
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced a new collaboration with United Therapeutics (UT), a leading biotec...
Tempus IPO: Stock price watched today as AI health-tech company starts Nasdaq trading
Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public.
Tempus soars 15% on the first day of trading, demonstrating investor appetite for a health tech with a promise of AI
Tempus, a genomic testing and data analysis company started by Eric Lefkosky, who previously founded Groupon, debuted on Nasdaq on Friday, rose about 15% on the opening
Tempus AI Surges in Nasdaq Debut Following IPO
Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq.
Tempus AI shares jump 8% in Nasdaq debut
Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.
Tempus AI CEO Eric Lefkofsky on going public: It's been an incredible journey
Tempus AI founder and CEO Eric Lefkofsky joins 'Squawk Box' to discuss taking the company public on Nasdaq later today, the origin of the company,
Tempus AI announces pricing of US IPO
SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece.
Tempus Announces Pricing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 pe...
Healthcare-technology company Tempus AI looks to raise $400 million in IPO
Tempus AI Inc. is about to give investors a way to play the intersection of medicine and artificial intelligence.
Tempus AI seeks up to $6.1 bln valuation in US IPO
Tempus AI is targeting a valuation of up to $6.10 billion in its initial public offering in the United States, the genetics testing company said on Wednesday.
Billionaire Groupon founder Lefkofsky is back with another IPO: AI healthtech Tempus
Eric Lefkofsky knows the public listing rodeo well and is about to enter it for a fourth time. The serial entrepreneur, whose net worth is estimated at nearly $4 billion, has already taken three busin...
Health-tech startup Tempus AI files for a $100 million IPO
Tempus AI, which provides data and analytics tools for precision medicine, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Tempus AI IPO Registration Document (S-1)
Tempus AI has filed to go public with an IPO on the NASDAQ.